Ketamine is not FDA approved for the treatment of PTSD. It is not FDA approved for the treatment of any psychiatric disorder. The only approved use of ketamine hydrochloride is as an injectable anesthetic for induction and maintenance of general anesthesia. Despite growing interest and a rising number of clinics offering ketamine for PTSD, the FDA has explicitly stated it has not determined that ketamine is safe and effective for this use.
What Ketamine Is Actually Approved For
Ketamine hydrochloride is a Schedule III controlled substance approved solely as an intravenous or intramuscular injection for general anesthesia. It has been used in operating rooms and emergency departments since the 1970s.
A related drug called Spravato (esketamine), which contains only one of the two mirror-image molecules found in regular ketamine, is approved as a nasal spray for two specific conditions: treatment-resistant depression in adults and depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. In both cases, it must be used alongside an oral antidepressant. Spravato is not approved for PTSD, anxiety, OCD, or any other psychiatric condition.
Why Clinics Still Offer It for PTSD
Doctors in the United States can legally prescribe FDA-approved medications for uses that haven’t been formally approved, a practice known as off-label prescribing. This is how ketamine ends up being used for PTSD in clinics across the country. The FDA is aware this is happening and has issued warnings specifically about compounded ketamine products being marketed for psychiatric disorders including PTSD, depression, anxiety, and OCD.
The distinction matters because off-label use means the drug hasn’t gone through the rigorous clinical trial process that would confirm it works safely and reliably for that condition. You’re relying on smaller studies, clinical judgment, and early evidence rather than the large-scale data the FDA normally requires.
What the Research Actually Shows
Early clinical trials suggest ketamine can reduce PTSD symptoms quickly, but the evidence base is still small. In a randomized clinical trial published in JAMA Psychiatry, a single intravenous ketamine infusion significantly reduced PTSD symptom severity compared to a sedative (midazolam) within 24 hours. Patients who received ketamine scored an average of 12.7 points lower on a standard PTSD symptom scale than those who received the sedative.
That speed is noteworthy. Traditional PTSD medications like SSRIs typically take weeks to produce noticeable effects, while ketamine’s impact was measurable within a day. In another trial, repeated infusions given three times per week over a 12-day period were associated with PTSD symptom relief lasting up to 41 days.
The typical protocol used in research involves a single IV infusion at 0.5 mg/kg delivered over 40 minutes. But these are relatively small studies, and they don’t yet answer critical questions about long-term safety, optimal dosing schedules, or which patients benefit most.
How Ketamine Works in the Brain
Ketamine operates through a fundamentally different pathway than traditional antidepressants or anti-anxiety medications. Rather than adjusting serotonin levels, it blocks a specific type of receptor involved in glutamate signaling, the brain’s primary excitatory chemical messenger. This blockade triggers a cascade that ultimately strengthens connections between neurons in brain circuits that regulate mood and stress responses.
This process, sometimes called synaptic potentiation, is essentially the brain forming and reinforcing new neural pathways. It may explain why ketamine can produce rapid changes in symptoms: instead of slowly shifting the chemical balance over weeks, it directly promotes the structural rewiring that underlies recovery from trauma-related conditions.
Side Effects and Safety Concerns
Ketamine’s side effects during and after infusion are well documented. The most common ones in the first 24 hours include blurred vision, dry mouth, restlessness, fatigue, nausea, poor coordination, and headache. Dissociation, a feeling of detachment from your body or surroundings, is one of the most notable effects and has caused some patients to discontinue treatment.
Blood pressure spikes are a real concern. In one clinical trial, three patients required medication to manage elevated blood pressure (systolic above 180 or diastolic above 100) during treatment. This makes cardiovascular monitoring during infusions essential.
There’s also a particular wrinkle for PTSD patients. Research on esketamine (the S-form of ketamine) found that patients experienced significantly increased acute PTSD symptoms, including dissociation, re-experiencing of trauma, and avoidance behaviors. Interestingly, this effect was seen with esketamine specifically but not with racemic ketamine (the standard form containing both molecular variants). This distinction hasn’t been fully explored yet, but it raises important questions about which form of the drug is appropriate for trauma-related conditions.
Ketamine is also a potentially addictive substance. Long-term oral ketamine use for psychiatric conditions has been associated with mild side effects like lightheadedness, sedation, and transient dissociation, but the risk of dependence with ongoing use remains a concern the FDA has highlighted.
Cost and Insurance Coverage
Because ketamine for PTSD is off-label, most insurance plans do not cover it. Few insurers reimburse off-label ketamine therapy for any psychiatric condition. You’ll typically pay out of pocket.
Costs vary widely depending on the clinic and the number of sessions. For context, Spravato (which is approved for depression, not PTSD) runs about $590 per session for the medication alone, plus the cost of the required medical visit. Annual costs for Spravato can range from $18,000 to $45,000. Janssen, the manufacturer, does offer a patient assistance program that reduces the cost to $10 per treatment up to a maximum benefit of $8,150 per year, but again, this applies to its approved uses for depression.
Off-label IV ketamine infusions at private clinics are generally less expensive per session than Spravato, but costs add up quickly when multiple infusions are needed. Some newer ancillary insurance products, like those offered by the company Enthea, have begun providing coverage for ketamine therapy specifically, though this remains uncommon.
What’s in the Pipeline
Several pharmaceutical companies are working to bring ketamine-based treatments through the formal FDA approval process. NRx Pharmaceuticals is developing NRX-100, a preservative-free IV ketamine formulation, and planned to file a New Drug Application in mid-2025. Their subsidiary, HOPE Therapeutics, is specifically targeting depression, PTSD, OCD, and related conditions using what they describe as “neuroplastic therapies” that promote new connections between brain cells.
NRX-100 has received Fast Track Designation from the FDA, which is designed to speed the review of drugs that address serious conditions. However, its primary development focus so far has been suicidal depression rather than PTSD specifically. No ketamine-based drug is currently in late-stage FDA trials with PTSD as the primary indication, which means formal approval for this use likely remains years away.